DE69711584D1 - Verfahren und zusammensetzungen zur bestimmung der empfindlichkeit und resistenz gegen antivirale wirkstoffe und screening für antivirale wirkstoffe - Google Patents

Verfahren und zusammensetzungen zur bestimmung der empfindlichkeit und resistenz gegen antivirale wirkstoffe und screening für antivirale wirkstoffe

Info

Publication number
DE69711584D1
DE69711584D1 DE69711584T DE69711584T DE69711584D1 DE 69711584 D1 DE69711584 D1 DE 69711584D1 DE 69711584 T DE69711584 T DE 69711584T DE 69711584 T DE69711584 T DE 69711584T DE 69711584 D1 DE69711584 D1 DE 69711584D1
Authority
DE
Germany
Prior art keywords
active substances
antiviral active
screening
compositions
resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69711584T
Other languages
English (en)
Other versions
DE69711584T2 (de
Inventor
J Capon
John Petropoulous
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monogram Biosciences Inc
Original Assignee
Virologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virologic Inc filed Critical Virologic Inc
Publication of DE69711584D1 publication Critical patent/DE69711584D1/de
Application granted granted Critical
Publication of DE69711584T2 publication Critical patent/DE69711584T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69711584T 1996-01-29 1997-01-29 Verfahren und zusammensetzungen zur bestimmung der empfindlichkeit und resistenz gegen antivirale wirkstoffe und screening für antivirale wirkstoffe Expired - Lifetime DE69711584T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59300996A 1996-01-29 1996-01-29
PCT/US1997/001609 WO1997027319A1 (en) 1996-01-29 1997-01-29 Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening

Publications (2)

Publication Number Publication Date
DE69711584D1 true DE69711584D1 (de) 2002-05-08
DE69711584T2 DE69711584T2 (de) 2002-11-07

Family

ID=24372979

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69711584T Expired - Lifetime DE69711584T2 (de) 1996-01-29 1997-01-29 Verfahren und zusammensetzungen zur bestimmung der empfindlichkeit und resistenz gegen antivirale wirkstoffe und screening für antivirale wirkstoffe
DE69739645T Expired - Lifetime DE69739645D1 (de) 1996-01-29 1997-01-29 Verfahren zur Bestimmung antiviraler Wirkstoff Suszeptibilität und Resistenz sowie antivirales Wirkstoff-Screening

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69739645T Expired - Lifetime DE69739645D1 (de) 1996-01-29 1997-01-29 Verfahren zur Bestimmung antiviraler Wirkstoff Suszeptibilität und Resistenz sowie antivirales Wirkstoff-Screening

Country Status (18)

Country Link
EP (2) EP1170380B1 (de)
JP (1) JP4183749B2 (de)
KR (1) KR100537153B1 (de)
CN (1) CN1263867C (de)
AP (1) AP9801360A0 (de)
AT (1) ATE447621T1 (de)
AU (1) AU732255B2 (de)
CA (1) CA2216126C (de)
DE (2) DE69711584T2 (de)
EA (1) EA005426B1 (de)
ES (1) ES2175355T3 (de)
HU (1) HUP9900388A3 (de)
IL (1) IL125464A (de)
NO (1) NO983421L (de)
NZ (1) NZ331376A (de)
PL (1) PL328068A1 (de)
RO (1) RO118887B1 (de)
WO (1) WO1997027319A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100336699B1 (ko) 1992-08-25 2002-05-13 윌리암스 로저 에이 레트로바이러스 프로테아제 저해제로서 유용한히드록시에틸아미노 술폰아미드
WO1999066068A2 (en) * 1998-06-19 1999-12-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method and kit for detecting resistance to antiviral drugs
NZ325912A (en) 1996-01-26 1999-01-28 Virco Nv Method of managing the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
AU8897698A (en) * 1997-07-30 1999-02-22 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
AU3474499A (en) * 1998-04-07 1999-10-25 Southern Research Institute High-throughput method for screening for antiviral activity
NZ508834A (en) * 1998-05-26 2004-06-25 Virologic Inc Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy
US7037644B1 (en) 1998-05-26 2006-05-02 Virologic, Inc. Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US20030148307A1 (en) 1998-06-19 2003-08-07 Department Of Health & Human Services, C/O Centers Of Disease Control And Prevention Method and kit for detecting resistance to antiviral drugs
US6787126B1 (en) 1998-06-19 2004-09-07 The United States Of America As Represented By The Department Of Health And Human Services Method and kit for detecting resistance to antiviral drugs
NZ508981A (en) * 1998-06-24 2004-02-27 Virologic Inc Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
ATE302287T1 (de) 1999-05-28 2005-09-15 Virco Nv Neue mutationsprofile der hiv-1 reverse transcriptase in verbindung mit phänotypischem medikamentresistenz
EP1326640A4 (de) * 2000-09-15 2004-12-15 Virologic Inc Nichtnucleosidischer reverse-transcriptase-hemmer als antiretrovirale therapie
AU2002212344B2 (en) * 2000-10-20 2007-05-17 Virco Bvba Establishment of biological cut-off values for predicting resistance to therapy
EP1356082A2 (de) 2000-10-20 2003-10-29 Virco Bvba Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-reverse-transkriptase
US7097970B2 (en) 2001-06-04 2006-08-29 Monogram Biosciences, Inc. Methods of evaluating viral entry inhibitors using patient derived envelope protein constructs
US7247439B1 (en) 2001-06-04 2007-07-24 Monogram Biosciences, Inc. Method of evaluating a patient antibody response to envelope proteins of a virus
DE60225587T2 (de) 2001-11-08 2009-04-02 Aaron Diamond Aids Research Center Protease assay zur kontrolle medikamentöser therapie
CA2490862A1 (en) 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
AU2003251732B2 (en) 2002-07-01 2008-09-18 Tibotec Pharmaceuticals Ltd. New mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
DE20218008U1 (de) 2002-11-21 2003-03-06 FESTO AG & Co., 73734 Esslingen Anordnung von mehreren Handhabungsvorrichtungen
US8603736B2 (en) 2004-06-07 2013-12-10 Monogram Biosciences, Inc. Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays
US8178291B2 (en) 2005-02-18 2012-05-15 Monogram Biosciences, Inc. Methods and compositions for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors
US20090215028A1 (en) 2005-02-18 2009-08-27 Ellen Paxinos Methods and Compositions for Determining Anti-HIV Drug Susceptibility and Replication Capacity of HIV
US20090087841A1 (en) 2005-05-27 2009-04-02 Monogram Biosciences, Inc. Methods and compositions for determining resistance of hiv-1 to protease inhibitors
WO2006133266A2 (en) 2005-06-06 2006-12-14 Monogram Biosciences, Inc. Methods for determining resistance or susceptibility to hiv entry inhibitors
WO2006133267A2 (en) 2005-06-06 2006-12-14 Monogram Biosciences, Inc. Methods and compositions for determining altered susceptibility of hiv-1 to anti-hiv drugs
US8114585B2 (en) 2006-06-13 2012-02-14 Monogram Biosciences, Inc. Method for determining human immunodeficiency virus (HIV) coreceptor utilization by examining gp41 molecular determinants
WO2008090185A1 (en) 2007-01-23 2008-07-31 Virco Bvba Method for designing a drug regime for hiv-infected patients
US9581595B2 (en) 2007-02-26 2017-02-28 Laboratory Corporation Of America Holdings Compositions and methods for determining whether a subject would benefit from co-receptor inhibitor therapy
WO2018030534A1 (ja) * 2016-08-10 2018-02-15 国立研究開発法人理化学研究所 Ｂ型肝炎治療用組成物、及びｂ型肝炎ウイルスの複製活性の評価方法
RU2646472C1 (ru) * 2016-10-07 2018-03-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации Способ оценки эффективности терапии инфекции вызванной вирусом герпеса человека 6 типа у детей
US10793876B2 (en) * 2016-12-29 2020-10-06 Virongy L.L.C. Retro- and lenti-HBV hybrid vectors and constructs
CN109722465B (zh) * 2019-01-07 2022-02-01 福建省疾病预防控制中心(福建省健康教育促进中心、福建省卫生检验检测中心) 一种hiv耐药检测载体和构建方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0291893A1 (de) * 1987-05-19 1988-11-23 The Du Pont Merck Pharmaceutical Company Stabile menschliche Zellinien, die ein Indikatorgenprodukt unter virusspezifischen genetischen Kontrollen exprimieren
EP0361749B1 (de) * 1988-09-27 1995-02-08 Dana Farber Cancer Institute Vektor, der ein replikationskompetentes HIV-I-Provirus und ein heterologes Gen enthält
HU209835B (en) * 1988-12-07 1994-11-28 Univ Osaka Res Found Method for producing of retrovirus protease, reverse transcriptase and integrase
DK0414475T3 (da) * 1989-08-25 1998-02-09 Chiron Corp Fremgangsmåder til dyrkning af HCV i B- eller T-lymfocyt-cellelinier
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
FR2700169B1 (fr) * 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
US5645982A (en) * 1993-08-19 1997-07-08 Systemix, Inc. Method for screening potential therapeutically effective antiviral agents
AU1923795A (en) * 1994-02-18 1995-09-04 University Of Washington Methods and compositions for screening for anti-aids drugs
US5733543A (en) * 1994-04-29 1998-03-31 Nabel; Gary J. Introduction of HIV-protective genes into cells by particle-mediated gene transfer
EP0772689B1 (de) * 1994-05-09 2007-12-19 Oxford Biomedica (UK) Limited Retrovirale vektoren mit verminderter rekombinationsrate
US5837464A (en) * 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
AU8897698A (en) * 1997-07-30 1999-02-22 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening

Also Published As

Publication number Publication date
KR19990082129A (ko) 1999-11-15
EP1170380A3 (de) 2003-05-02
JP4183749B2 (ja) 2008-11-19
AU1952897A (en) 1997-08-20
EP0852626A1 (de) 1998-07-15
HUP9900388A3 (en) 2005-03-29
WO1997027319A1 (en) 1997-07-31
DE69739645D1 (de) 2009-12-17
NO983421D0 (no) 1998-07-24
IL125464A0 (en) 1999-03-12
RO118887B1 (ro) 2003-12-30
EP0852626A4 (de) 1999-08-25
NZ331376A (en) 2000-03-27
AP9801360A0 (en) 1998-12-31
CA2216126C (en) 2009-03-31
HUP9900388A2 (hu) 1999-05-28
EP1170380A2 (de) 2002-01-09
AU732255B2 (en) 2001-04-12
CN1263867C (zh) 2006-07-12
JP2000503849A (ja) 2000-04-04
CA2216126A1 (en) 1997-07-31
NO983421L (no) 1998-09-25
DE69711584T2 (de) 2002-11-07
PL328068A1 (en) 1999-01-04
IL125464A (en) 2007-12-03
EP0852626B1 (de) 2002-04-03
EA199800669A1 (ru) 1999-02-25
CN1213407A (zh) 1999-04-07
EP1170380B1 (de) 2009-11-04
EA005426B1 (ru) 2005-02-24
ATE447621T1 (de) 2009-11-15
ES2175355T3 (es) 2002-11-16
KR100537153B1 (ko) 2006-12-15

Similar Documents

Publication Publication Date Title
DE69711584D1 (de) Verfahren und zusammensetzungen zur bestimmung der empfindlichkeit und resistenz gegen antivirale wirkstoffe und screening für antivirale wirkstoffe
DE69130000D1 (de) Verfahren zur Messung, Analyse und Bestimmung der Bodenstruktur
DE69516152D1 (de) Zusammensetzungen und verfahren zur anewndung in nachweis von analyten
DE69728310D1 (de) Belastungsmessung eines Elementes und Überwachung seiner Integrität
DE69815240D1 (de) Verfahren und Anordnung zur Messung des Widerstandes von Erdformationen
DE69522415D1 (de) Batterierestkapazitätsmesser und Verfahren zur Bestimmung der Restkapazität
DE60035733D1 (de) Einrichtung und Verfahren zur quantitativen Bestimmung der Aenderung in einem Elektrokardiogrammsignal
DE59010805D1 (de) Widerstandsmessfühler zur erfassung von gaszusammensetzungen und verfahren zu seiner herstellung
PT832082E (pt) Derivados de n-heteroaril-piridinossulfonamidas e sua utilizacao como antagonistas de endotelina
NO20003228D0 (no) MÕleutrustning for Õ bestemme konsentrasjon av biologisk materiale
DE69628999D1 (de) ATP-Eliminator und Verfahren zur Bestimmung von biologischen Zellen
DE69421375D1 (de) Verfahren zur Bestimmung der Herzgefässfunktion
ATA126296A (de) Verfahren und messanordnung zur optischen bestimmung der totalen hämoglobinkonzentration
DE69839778D1 (de) Widerstand und verfahren zu seiner herstellung
DE60040208D1 (de) Mehrelektroden-vorrichtung und -verfahren zur messung von zusammensetzungen
DE69333957D1 (de) Bestimmung und Analyse der Knochenstruktur
PT821234E (pt) Suporte de teste diagnostico com um campo de teste multicamada e metodo para determinacao de substancias a analisar utilizando o mesmo
PT941056E (pt) Composicoes de esfingomielinase e sua utilizacao
DE59707425D1 (de) Verfahren und teststreifen zur bestimmung eines analyten
DE69515643D1 (de) Fühlerprobe
DE69827437D1 (de) Verfahren zur Analyse und zur Verhinderung von Korrosion
DE69822873D1 (de) Zusammensetzungen und verfahren zur gewichtsverringerung
NO950575D0 (no) Prövesonde for fuktighetsmåling i byggematerialer
DE69725774D1 (de) Verfahren und Gerät zur Messung von Strom-Spannungs-Kennlinien von Solarzellen
ID26118A (id) Celana tipe celana pendek sekali pakai dan proses pembuatannya

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 852626

Country of ref document: EP

Representative=s name: VOSSIUS & PARTNER, 81675 MUENCHEN, DE